View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
THURSDAY, Jan. 19 (HealthDay News) -- Direct-acting antiviral agents may be effective for treating patients with chronic hepatitis C virus (HCV) genotype 1 who don't respond to peginterferon and ribavirin therapies, according to a study published in the Jan. 19 issue of the New England Journal of Medicine.
Anna S. Lok, M.D., of the University of Michigan in Ann Arbor, and colleagues studied a cohort of 21 patients with HCV genotype 1 infection who had not responded after 12 weeks of treatment with peginterferon and ribavirin. Eleven patients were assigned to group A to receive daclatasvir (60 mg daily) and asunaprevir (600 mg twice daily), while group B, with 10 patients, received daclatasvir and asunaprevir in combination with peginterferon alfa-2a and ribavirin.
The researchers found that 36 percent of group A (four patients) had a sustained virologic response at 12 and 24 weeks after treatment. Six patients had viral breakthrough during treatment, with resistance mutations identified in all cases. One patient had a viral response at the end of therapy, but relapsed. All patients in group B had a sustained virologic response at 12 weeks, and this was maintained at 24 weeks in nine of the patients. In both groups, the most common adverse event was diarrhea.
"Overall, these results suggest that further research with combinations of direct-acting antiviral agents, with or without peginterferon and ribavirin, is warranted," the authors conclude.
The study was funded by Bristol-Myers Squibb, which manufactures daclatasvir and asunaprevir; several study authors and the editorial author disclosed financial relationships with pharmaceutical companies, including Bristol-Myers Squibb.
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top